Publications by authors named "Margherita Nardin"
Wilms tumor (WT), or nephroblastoma, is an uncommon malignant neoplasm occurring in the kidney of pediatric patients. Its extrarenal location is extremely rare and has been reported in various sites, including the female genital tract, with only 9 cases arising in the uterine corpus. We present the case of an adult woman who underwent total abdominal hysterectomy due to a uterine mass causing persistent abdominal pain.
View Article and Find Full Text PDFArticle Synopsis
- PARP inhibitors have shown significant benefits in prolonging progression-free survival (PFS) for patients with relapsed, platinum-sensitive epithelial ovarian cancer (OC).
- This study analyzed the effects of the most recent platinum-based chemotherapy on the response to PARP inhibitors in 96 advanced OC patients.
- Results indicated that those who received pegylated liposomal doxorubicin-oxaliplatin (PLD-Ox) prior to PARP inhibitors experienced better overall survival (OS) and PFS, especially in patients with BRCA mutations.
Purpose: To establish size-dependent DRL and to estimate the effectiveness of the size-dependent DRLs over size-independent DRLs for a CT exposure optimization process.
Methods: The study included 16,933 adult CT body examinations of the most common CT protocols. Acquisitions were included following an image quality assessment.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
October 2021
Article Synopsis
- Routine antithrombotic prophylaxis is not advised for advanced cancer patients undergoing chemotherapy, and the impact of bevacizumab on thromboembolic risks in ovarian cancer is unclear.
- A secondary analysis of the MITO-16A/MaNGO-OV2A trial assessed thromboembolic events and antithrombotic therapy among patients receiving platinum-based chemotherapy with bevacizumab.
- The study found a 6.0% incidence of thromboembolic events which were not linked to patient characteristics, antithrombotic use, or overall survival outcomes.
Objective: To explore the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab.
Methods: A multicenter, phase IV, single arm trial was performed. Patients with advanced (FIGO (International Federation of Gynecology and Obstetrics) stage IIIB-IV) or recurrent, previously untreated, ovarian cancer received carboplatin (AUC (area under the curve) 5), paclitaxel (175 mg/m) plus bevacizumab (15 mg/kg) on day 1 for six 3-weekly cycles followed by bevacizumab single agent (15 mg/kg) until progression or unacceptable toxicity up to a maximum of 22 total cycles.
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors with a strong genetic background. The mainstay of treatment for PCC/PGLs is surgery. However, for unresectable lesions, no curative treatment is currently available.
View Article and Find Full Text PDFArticle Synopsis
- The study assessed the effectiveness of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in monitoring ovarian cancer (OC) patients, particularly focusing on its correlation with cancer antigen-125 (CA125) levels and its prognostic value.
- A total of 125 OC patients were analyzed, revealing that FDG PET/CT had a very high sensitivity (98.6%) for detecting recurrent disease and modest sensitivity (72.7%) for evaluating therapy response, compared to CA125's 72% sensitivity.
- The findings indicated that negative results from both CA125 and FDG PET/CT scans were linked to significantly higher global survival rates, with age and the presence of peritoneum recurrence
Article Synopsis
- A retrospective study analyzed the effectiveness of trabectedin combined with pegylated liposomal doxorubicin (PLD) in 34 patients with platinum-sensitive relapsed ovarian cancer who had undergone a median of 3 previous treatments.
- The treatment yielded an objective response rate (ORR) of 32.4%, with median progression-free survival (PFS) of 6.1 months and overall survival (OS) of 16.3 months, particularly benefiting those with partially platinum-sensitive disease.
- The findings align with previous clinical trials, endorsing trabectedin/PLD as a viable treatment option for this patient group, although some reported side effects included nausea, mucositis, and changes in liver enzymes.
Recurrent type I endometrial cancer (EC) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic cancer patients treated with bevacizumab may also take metformin, whether metformin modulates response to anti-VEGF therapy has not yet been investigated.
View Article and Find Full Text PDFPositive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
Tumori
March 2011
Aims And Background: To assess feasibility and toxicity of intraperitoneal administration of cisplatin and paclitaxel, followed by intravenous chemotherapy in pretreated patients with suboptimal ovarian cancer (residuum >1 cm) or primary peritoneal tumor, and suffering from ascites and/or intestinal obstruction.
Methods: Fourteen relapsed ovarian cancer patients, 5 of whom were platinum sensitive (platinum-free interval >6 mo), 7 platinum-resistant (platinum-free interval <6 mo), and 2 platinum-refractory, received one cycle of intraperitoneal cisplatin, 100 mg/m2 on day 1, and two cycles of intraperitoneal paclitaxel, 120 mg/m2 on days 8 and 14. Intravenous chemotherapy was administrated 4 weeks following the last intraperitoneal paclitaxel instillation.